14 January 2026
14 January 2026
Pfizer CEO Bourla anticipates that the obesity market will “grow very fast” and reach $150bn by 2030.
Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn projected consensus 2028 Keytruda sales.
Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.
Full pipelines and rising revenues lead rare disease biotechs to restyle themselves as more mature, global biopharma companies.
Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.
Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of Avidity Biosciences set to close later this year.
Sanofi has doubled down on R&D in a bid to brace for lost revenue from Dupixent's looming patent expiry.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
